Puma Biotechnology (PBYI) Research & Development (2012 - 2026)

Puma Biotechnology has reported Research & Development for 15 years, with the latest figure at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 42.79% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $68.0 million (up 23.16% YoY), and the FY2025 full-year result was $62.1 million, up 12.98% from the prior year.
• Research & Development for Q1 2026 stood at $19.8 million, up from $16.8 million in the prior quarter.
• The five-year high for Research & Development was $19.8 million in Q1 2026, with the low at $7.0 million in Q3 2022.
• Historically, Research & Development has averaged $13.8 million across 5 years, with a median of $13.6 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development plunged 62.84% — and 2023, when it soared 63.51%.
• Puma Biotechnology's Research & Development stood at $13.8 million in 2022, then retreated by 6.61% to $12.9 million in 2023, then grew by 17.84% to $15.2 million in 2024, then advanced by 11.02% to $16.8 million in 2025, then advanced by 17.54% to $19.8 million in 2026.
• The last three Research & Development figures came in at $19.8 million (Q1 2026), $16.8 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.